Metalytics Joins Life Science Industry Leaders on Science Exchange
Retrieved on:
Tuesday, December 21, 2021
PARK, Respiration (physiology), Thyssenkrupp Materials Services, RESEARCH, Diabetes, Amgen, MFA, CEO, Investment, Merck, Metabolism, Gilead Sciences, Biotechnology, Cell, Genentech, CMOS, Research, Disease, Science, Synthetic biology, Obesity, Metabolic flux analysis, Science Exchange (company), Cros, Biofuel, Cancer, R, Contract, Fine chemical
RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2021 /PRNewswire/ --Metalytics, the world's leading provider of metabolic flux analysis (MFA) to the life science sector, is proud to announce that it is now a verified provider on Science Exchange, the online platform for outsourced research and development (R&D).
Key Points:
- RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2021 /PRNewswire/ --Metalytics, the world's leading provider of metabolic flux analysis (MFA) to the life science sector, is proud to announce that it is now a verified provider on Science Exchange, the online platform for outsourced research and development (R&D).
- The Science Exchange network of 3,500+ CROs, CMOs, and academic labs enables research teams to initiate projects without the need for individual contracts.
- Science Exchange's enterprise clients include major drug and biotechnology companies, including Merck, Amgen, Gilead Sciences, and Genentech.
- "Joining Science Exchange is yet another example of our commitment to being the leading provider of metabolic flux analysis services to the life science industry", said Eric Cumming, CEO of Metalytics.